- 2020 Snapshot: State of the Oncology Workforce in America. *JCO Oncol Pract*. 2021;17(1):30.
- Agunwamba AA, Zhu X, Sauver JS, Thompson G, Helmueller L, Rutten LJF. Barriers and facilitators of colorectal cancer screening using the 5As framework: a systematic review of US studies. *Prev Med Rep*. 2023;35:102353.
- American Cancer Society. Access to biomarker testing. Accessed November 14, 2023. https://www.fightcancer.org/what-we-do/access-biomarker-testing
- The American Journal of Managed Care. Improving HER2 biomarker testing in metastatic colorectal cancer. August 12, 2022. Accessed November 14, 2023. https://www.ajmc.com/view/improving-her2-biomarker-testing-in-metastatic-colorectal-cancer
- André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med.* 2020;383(23):2207-2218.
- Associazione Italiana di Oncologia Medica. Accessed November 14, 2023. https://www.aiom.it/wp-content/uploads/2019/07/20191019SS_31_Cogoni.pdf
- Bartley AN, Mills AM, Konnick E, et al. Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline From the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. *Arch Pathol Lab Med*. 2022;146(10):1194-1210.
- Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov.* 2011;1(6):508-523.
- Browne S, Dowie A, Mitchelle E, et al. Patients' needs following colorectal cancer diagnosis: where does primary care fit in? *Br J Gen Pract.* 2011;61(592):e692-699.
- CancerCare. What people with cancer should know about biomarker testing. Accessed November 14, 2023. https://media.cancercare.org/publications/original/464-BioMarker_PatientFacing_About_v3.pdf
- Cancer Network. Recap: treatment sequencing and testing strategies in HER2+ colorectal cancer. June 21, 2023. Accessed November 14, 2023. https://www.cancernetwork.com/view/recap-treatment-sequencing-and-testing-strategies-in-her2-colorectal-cancer
- Carethers JM, Doubeni CA. Causes of socioeconomic disparities in colorectal cancer and intervention framework and strategies. *Gastroenterology*. 2020;158(2):354-367.
- Cavaletti G, Marmiroli P. Management of oxaliplatin-induced peripheral sensory neuropathy. *Cancers*. 2020;12(6):1370.
- Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2023;34(1):10-32.
- Coughlin SS. Social determinants of colorectal cancer risk, stage, and survival: a systematic review. *Int J Colorectal Dis*. 2020;35(6):985-995.
- El-Khoueiry AB, et al. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). *J Clin Oncol.* 2023;41(suppl 4):abstr LBA8.
- Fight CRC. The importance of biomarkers in colorectal cancer treatment. September 7, 2022. November 14, 2023. https://fightcolorectalcancer.org/blog/biomarkers-and-colorectal-cancer/
- Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. *J Natl Cancer Inst.* 2014;106(4):dju032.
- Gutierrez C, McEvoy C, Munshi L, et al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. *Crit Care Med.* 2020;48(1):10-21.

- Helwick C. MOUNTAINEER: tucatinib plus trastuzumab active in metastatic colorectal cancer. August 25, 2022. Accessed November 14, 2023. https://ascopost.com/issues/august-25-2022/mountaineer-tucatinib-plus-trastuzumab-active-in-metastatic-colorectal-cancer/
- Iyer P, Deng M, Handorf EA, Nakhoda S, Dotan E. Assessing oncologists' adoption of biomarker testing in metastatic colorectal cancer using real-world data. *JNCI Cancer Spectr*. 2022;6(6):pkac065.
- Kopetz S, McDonough SL, Lenz H-J, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). *J Clin Oncol*. 2017;35(15):abstr 3505.
- Kuwada SK, Scaife CL, Kuang J, et al. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. *Int J Cancer.* 2004;109(2):291-301.
- The Lancet Gastroenterology Hepatology. Addressing inequities in colorectal cancer. *Lancet Gastroenterol Hepatol*. 2020;5(11):955.
- Lewis MA, Stansfield L, Kelton JM, Lieu CH. biomarker testing trends in patients with metastatic colorectal cancer who live in rural areas and urban clusters in the US. *Oncologist*. 2023;28(11):e1118-e1122.
- Liu F, Ren C, Jin Y, et al. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. *Virchows Arch*. 2020;476(3):391-398.
- Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. *Exp Mol Med*. 2018;50(1):e416.
- Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. *Mol Cancer*. 2022;21(1):79.
- Madhusoodanan J. Health-care inequality could deepen with precision oncology. *Nature*. 2020;585:S13-S15.
- Markt SC, Booker BD, Bensken W, et al. Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer. *Cancer Med*. 2023;12(2):1850-1859.
- Mauri G, Vitiello PP, Sogari A, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. *Br J Cancer.* 2022;127(3):394-407.
- Mohammad NS, Nazil R, Zafar H, Fatima S. Effects of lipid based multiple micronutrients supplement on the birth outcome of underweight pre-eclamptic women: a randomized clinical trial. *Pak J Med Sci*. 2022;38(1):219-226.
- Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. *J Clin Oncol*. 2023;41(3):678-700.
- Moss JL, Pinto CN, Srinivasan S, Cronin KA, Croyle RT. Persistent poverty and cancer mortality rates: an analysis of county-level poverty designations. *Cancer Epidemiol Biomarkers Prev*. 2020;29(10):1949-1954.
- Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. *Chem Pharm Bull (Tokyo)*. 2019;67(3):173-185.
- Nakamura N, Shiraiwa H, Haruna Y, et al. Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand-foot syndrome in cancer patients: a retrospective study, *J Pharm Health Care Sci*. 2021;7(1):8.
- National Comprehensive Cancer Network. Guidelines V3. 2023. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
- National Comprehensive Cancer Network. Guidelines V5. 2023. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461
- Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. *Clin Cancer Res*. 2016;22(20):5097-5108.
- Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. *Cancer Sci.* 2016;107(7):1039-1046.

- Patel YP, Husereau D, Leighl NB, Melosky B, Nam J. Health and budget impact of liquid-biopsy-based comprehensive genomic profile (CGP) testing in tissue-limited advanced non-small cell lung cancer (aNSCLC) patients. *Curr Oncol.* 2021;28(6):5278-5294.
- Puccini A, Seeber A, Berger MD. Biomarkers in metastatic colorectal cancer: status quo and future perspective. *Cancers (Basel)*. 2022;14(9):4828.
- Quandt D, Zucht HD, Amann A, et al. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. *Oncotarget*. 2017;8(29):48507-48520.
- Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *J Clin Oncol*. 2017;35(13):1453-1486.
- Serelli-Lee V, Ito K, Koibuchi A, et al. A state-of-the-art roadmap for biomarker-driven drug development in the era of personalized therapies. *J Pers Med*. 2022;12(5):669.
- Siena S, Sartore-Bianchi A, Trusolino L, et al. Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. *J Clin Oncol*. 2015;33(suppl 3):565-565.
- Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2023;24(5):496-508.
- Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. *Oncologist*. 2012;17(4):513-524.
- Sun X-x, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. *Acta Pharmacol Sin*. 2015;36(10):1219-1227.
- Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated *BRAF* V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. *J Clin Oncol*. 2021;39(4):273-284.
- Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. *Pharmacol Ther*. 2018;181:126-142.
- Tsuji A, Ohori H, Yamaguchi T, et al. The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). *J Clin Oncol*. 2021,39(suppl 15):abstr 3501.
- Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with *BRAF* V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. *J Clin Oncol*. 2019;37(17):1460-1469.
- Watanabe T, Tsuji A, Shiozawa M, et al. Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: the DEEPER trial (JACCRO CC-13). *J Clin Oncol*. 2021,39(3 suppl):abstr 86.
- Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. *Nat Commun*. 2023;14(1):3332.